Loss of IGF2 imprinting: A potential marker of colorectal cancer risk

Science

Volumn 299, Issue 5613, 2003, Pages 1753-1755

  Cui, Hengmi ^a   Cruz Correa, Marcia ^a   Giardiello, Francis M ^a   Hutcheon, David F ^a   Kafonek, David R ^a   Brandenburg, Sheri ^a   Wu, Yiqian ^a   He, Xiaobing ^a   Powe, Neil R ^a,b   Feinberg, Andrew P ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; DNA; PROBABILITY; RISK ASSESSMENT;

COLORECTAL CANCER (CRC);

TUMORS;

CANCER; GENE; IMPRINTING;

ADULT; ARTICLE; CANCER GENETICS; CANCER RISK; COLONOSCOPY; COLORECTAL CARCINOMA; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE MARKER; FAMILY HISTORY; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOME IMPRINTING; HUMAN; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; POPULATION GENETICS; PREDICTION; PRIORITY JOURNAL;

ADOLESCENT; AGING; CHILD; COLON; COLORECTAL NEOPLASMS; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FAMILY HEALTH; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOMIC IMPRINTING; HUMANS; INSULIN-LIKE GROWTH FACTOR II; INTESTINAL MUCOSA; LYMPHOCYTES; MALE; ODDS RATIO; PILOT PROJECTS; TUMOR MARKERS, BIOLOGICAL;

EID: 0037436509     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1080902     Document Type: Article

References (21)

1. K. Markey, L. Axel, D. Ahnen, Curr. Gastroenterol. Rep. 4, 404 (2002).
2. W. S. Samowitz et al., Gastroenterology 121, 830 (2001).
3. A. Percesepe et al., J. Clin. Oncol. 19, 3944 (2001).
4. A. P. Feinberg, in The Metabolic and Molecular Bases of Inherited Disease, C. R. Scriver et al., Eds. (McGraw-Hill, New York, 2002), chap. 18.
5. J. D. Ravenel et al., J. Natl. Cancer Inst. 93, 1698 (2001).
6. H. Lahm et al., Br. J. Cancer 65, 341 (1992).
7. M. C. Gelato, J. Vassalotti, J. Clin. Endocrinol. Metab. 71, 1168 (1990).
8. O. M. El-Badry et al., Cell Growth Differ. 1, 325 (1990).
9. D. Yee et al., Cancer Res. 48, 6691 (1988).
10. T. Lamonerie, C. Lavialle, H. Haddada, O Brison, Int. J. Cancer 61, 587 (1995).
11. G. J. Pommier et al., Cancer Res. 52, 3182 (1992).
12. H. Cui et al., Nature Med. 4, 1276 (1998).
13. Written informed consent was obtained from all subjects. The protocol was approved by the Johns Hopkins Joint Committee on Clinical Investigation.
14. Materials and methods are available as supporting material on Science Online.
15. J. P. Issa et al., Proc. Natl. Acad. Sci. U.S.A. 93, 11757 (1996).
16. E. R. Fearon, B. Vogelstein, Cell 61, 759 (1990).
17. H. Cui et al., data not shown.
18. H. Cui et al., Cancer Res. 62, 6442 (2002).
19. T. Sakatani et al., Biochem. Biophys. Res. Commun. 283, 1124 (2001).
20. M. J. Khoury, L. L. McCabe, E. R. McCabe, N. Engl. J. Med. 348, 50 (2003).
21. We thank M. Graber for preparing the manuscript. This work was supported by NIH grants R01 CA65145 (to A.P.F.) and K07 CA092445 (to M.C.-C.), the Maryland Cigarette Restitution Fund, and the John G. Rangos Sr. Family Charitable Foundation (to F.M.G.). Under a licensing agreement between Epigenomics AG and the Johns Hopkins University, H. C., M.C.-C., and A.P.F. are entitled to a share of royalty received by the university on sales of licensed technology described in this article, A.P.F. is also a paid consultant to Epigenomics AG. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.